Post-traumatic stress disorder (PTSD) is a chronic psychiatric condition that noticeably impairs quality of life, although only a limited proportion of newly diagnosed patients seek prescription drug treatment. A few modestly efficacious drugs are formally approved to treat PTSD; antidepressants and antipsychotics are the most commonly prescribed. Opportunity exists for emerging agents that offer improved efficacy and safety and tolerability. Improvements in efficacy include effects on core PTSD symptoms and on secondary disorders arising from PTSD (e.g., symptoms of anxiety disorders, proclivity toward substance abuse). Areas of improvement for safety and tolerability include effects such as weight gain and loss of libido. Commercial opportunity likely exists for a new PTSD drug that addresses these inadequacies and other areas of large unmet need (e.g., drugs that improve cognitive function or aid in complete remission).
- What are the treatment drivers and goals for PTSD?
- What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- What are the top areas of unmet need and opportunity in PTSD, and what do therapies in development for PTSD, such as Lundbeck’s Rexulti / Rxulti and Nobilis Therapeutics’ NBTX-001, have to offer?
- What trade-offs in drug price and performance across key drug attributes are surveyed psychiatrists willing to make?
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. psychiatrists and 32 European psychiatrists fielded in March 2020
Key companies: GSK, Pfizer, Roche, Allergan, and AstraZeneca
Key drugs: prazosin, sertraline, paroxetine, diazepam, gabapentin, bupropion SR, and quetiapine
- Post Traumatic Stress Disorder - Unmet Need - Detailed, Expanded Analysis (US/EU)
Author(s): Audreza Das, P.G. Dip.
Audreza Das is a Senior Analyst in the CNS/Ophthalmology team at Decision Resources Group
She has authored content across indications, including neuropathic pain, age-related macular degeneration, treatment-related depression, painful diabetic neuropathy, and migraine. Ms. Das has previously worked at Novo Nordisk, as a Market Analyst for European markets. Previous experience at a SME, included developing disease competitive landscapes, covering global conferences etc. Ms. Das received her B.E. degree in Biotechnology from Birla Institute of Technology, a deemed university and her P.G. Diploma in Cancer Immunology & Biotechnology from University of Nottingham.